Consenso sobre riesgo de complicaciones infecciosas en pacientes usuarios de medicamentos biológicos seleccionados. Parte II: Guía clínica chilena de Prevención de Infecciones Asociadas al Uso de Terapias Biológicas (PREVITEB)

Simple item page
dc.catalogadordfo
dc.contributor.authorCerón Araya, Inés María
dc.contributor.authorVizcaya Altamirano, María Cecilia
dc.contributor.authorGambra, Pilar
dc.contributor.authorFerres Garrido, Marcela Viviana
dc.contributor.authorBidart, Teresa
dc.contributor.authorLépez Quizhpi,Tania Lorena
dc.contributor.authorAcuña, María Paz
dc.contributor.authorÁlvarez, Ana María
dc.contributor.authorZubieta, Marcela
dc.contributor.authorDurán, Luisa
dc.contributor.authorRabagliati Borie, Ricardo Miguel
dc.date.accessioned2024-05-23T15:43:47Z
dc.date.available2024-05-23T15:43:47Z
dc.date.issued2019
dc.description.abstractThe use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of 2 manuscripts. This second part is a guideline that details these recommendations through screening strategies, prophylactic therapies and vaccines indications for bacterial, mycobacterial, viral, fungal and parasitic infections, both for adults and children.
dc.fuente.origenConveris
dc.identifier.doi10.4067/S0716-10182019000500616
dc.identifier.eissn0717-6341
dc.identifier.issn0716-1018
dc.identifier.pubmedid31859803
dc.identifier.scopusid2-s2.0-85075892746
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/85749
dc.identifier.wosidWOS:000499652900009
dc.information.autorucEscuela de Medicina; Ceron Araya Ines Maria; 0000-0002-6838-4982; 9404
dc.information.autorucEscuela de Medicina; Vizcaya Altamirano Maria Cecilia; 0000-0003-1309-9778; 7645
dc.information.autorucEscuela de Medicina; Ferres Garrido Marcela Viviana; 0000-0001-9415-4657; 66180
dc.information.autorucEscuela de Medicina; Lopez Quizhpi Tania Lorena; S/I; 209551
dc.information.autorucEscuela de Medicina; Rabagliati Borie Ricardo Miguel; S/I; 59169
dc.issue.numero5
dc.language.isoes
dc.nota.accesoContenido parcial
dc.pagina.final628
dc.pagina.inicio616
dc.revistaRevista Chilena de Infectologia
dc.rightsacceso restringido
dc.subjectRiesgo de infección
dc.subjectTerapias biológicas
dc.subjectHospedero inmunocomprometido
dc.subjectPrevención
dc.subjectGuía clínica.
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleConsenso sobre riesgo de complicaciones infecciosas en pacientes usuarios de medicamentos biológicos seleccionados. Parte II: Guía clínica chilena de Prevención de Infecciones Asociadas al Uso de Terapias Biológicas (PREVITEB)
dc.title.alternativeConsensus of infectious complications in patients treated with selected biological therapies. Second part: Chilean Guidelines for Prevention of Infections associated to use of Biological Therapies (PREVITEB)
dc.typeartículo
dc.volumen36
sipa.codpersvinculados9404
sipa.codpersvinculados7645
sipa.codpersvinculados66180
sipa.codpersvinculados209551
sipa.codpersvinculados59169
sipa.trazabilidadConveris;20-07-2021
Files
Collections
Artículos de revistas